BridgeMD
New treatment option for Atrial Fibrillation
Official title Acute Atrial Fibrillation and Flutter Treated Electively
ClinicalTrials.gov ID: NCT04267159
What this study is testing
- What it's testing
- The AFFELECT -study compares two types of treatment modalities for acute atrial fibrillation or flutter for patients in whom rhythm control is desirable. The main purpose is to observe if these arrhythmias can be safely treated electively (within 5-9 days).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults
You may be able to join if
- Patients presenting with acute (\<48hours) atrial fibrillation or atrial flutter to ER
- Planned acute rhythm control for the arrhythmia by the attending physician in ER
- Good perceived health as assessed by attending physician in ER
- Resting heart rate 110bpm or lower before or after adequate rate control therapy
You likely can't join if
- Haemodynamically stable (mean arterial pressure above 60mmHg)
- Need for acute restoration of sinus rhythm due to some other somatic cause
- No other major complicating acute illness (e.g. decompensated HF or acute MI)
- Anticoagulation not safe
- Mechanical heart valve or mitral stenosis
- The need for prolonged (\>24h) hospitalization due to any cause
See the full eligibility criteria
- Patients presenting with acute (\<48hours) atrial fibrillation or atrial flutter to ER
- Planned acute rhythm control for the arrhythmia by the attending physician in ER
- Good perceived health as assessed by attending physician in ER
- Resting heart rate 110bpm or lower before or after adequate rate control therapy
- Haemodynamically stable (mean arterial pressure above 60mmHg)
- Need for acute restoration of sinus rhythm due to some other somatic cause
- No other major complicating acute illness (e.g. decompensated HF or acute MI)
- Anticoagulation not safe
- Mechanical heart valve or mitral stenosis
- The need for prolonged (\>24h) hospitalization due to any cause
- Exceptionally high risk for thromboembolic events (e.g. history of thromboembolic stroke regardless of adequate anticoagulation)
- Transesophageal echocardiography contraindicated
The study team makes the final eligibility decision.
Where it's taking place
- Jyväskylä, Central Finland, Finland
- Hämeenlinna, Kanta-Häme, Finland
- Lahti, Paijat-Hame Region, Finland
- Tampere, Pirkanmaa, Finland
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Jyväskylä, Central Finland, Finland; Hämeenlinna, Kanta-Häme, Finland; Lahti, Paijat-Hame Region, Finland; Tampere, Pirkanmaa, Finland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.